Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOCUS: Solriamfetol for Adults with ADHD
NCT05972044Phase 3Completed
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- Jul 2023
- Primary completion
- Feb 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of solriamfetol in attention deficit hyperactivity disorder (ADHD), sponsored by Axsome Therapeutics, Inc.. Started Jul 2023; status: completed.
02
Drugs
solriamfetol
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT05972044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05972044.